Clinical Trial Update: A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating serplulimab with docetaxel + S-1 vs docetaxel + S-1 as adjuvant therapy in stage IIIc gastric cancer; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• S-1 (tegafur/gimeracil/oteracil)
• Serplulimab (serplulimab)

Snippet

Sponsor: RenJi Hospital | Conditions: Serplulimab,Gastric Cancer, Adjuvant Therapy | Phase 2 | Status: UNKNOWN